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Notch1 is a transcription factor important for T-cell development. Notch1 is active in double negative (DN) thymocytes, while
being depressed in double positive (DP) thymocytes. Synchronously, the expression of Bcl-2 becomes downregulated during the
transition from DN to DP thymocytes. We previously observed that overexpression of an intracellular active Notch1 (ICN) in
Bcl-2-positive 2B4 T cells leads to the transcription of Notch1-regulated genes. However, these genes were not induced in Bcl-
2-negative DP PD1.6 thymic lymphoma cells overexpressing ICN. Here we show that, when Bcl-2 is simultaneously introduced
into these cells, Notch-regulated genes are transcribed. Only in the presence of both Bcl-2 and ICN, PD1.6 thymic lymphoma
cells become resistant to glucocorticoid (GC)-induced apoptosis. Our data suggest that Bcl-2 plays a role in modulating Notch1
function in T cells.
1.Introduction
Notch1 signaling plays a critical role in promoting cell
growth,proliferation,andsurvivalofimmatureTcells[1].In
the thymus, Notch signals are critical throughout the double
negative (DN) stages for the maintenance of T-cell speciﬁca-
tion and for continued diﬀerentiation of αβ T cells past the
β-selection checkpoint [2]. Upon interaction with its ligands
(e.g., Delta-like 1, Delta-like 4, Jagged 1, and Jagged 2), the
Notch1 protein undergoes two proteolytic events, leading
to the release of the intracellular Notch domain (ICN).
Subsequently, ICN translocates to the nucleus and activates
transcription of target genes through its association with C-
promoter binding factor 1-recombination binding protein
Jκ (CBF1-RBPJκ) and various members of the Mastermind
family [2].
Notch signaling is active in DN, CD4+, and CD8+ single
positive (SP) thymocytes, while being repressed in CD4+8+
double positive (DP) thymocytes [3, 4]. Similarly, DN,
CD4+, and CD8+ SP thymocytes express elevated levels of
Bcl-2, whereas DP thymocytes express low levels of Bcl-2 [5,
6]. Both Notch1 [3, 7, 8] and Bcl-2 [9–11] confer resistance
to glucocorticoid (GC)-induced apoptosis. However, this
resistance is partial as prolonged exposure to GCs leads to
apoptosis of immature T cells overexpressing either Notch1
or Bcl-2 [8–10]. Bcl-2 is an antiapoptotic protein that regu-
lates apoptosis along the intrinsic mitochondrial apoptosis
pathway [12]. The alterations in Notch signaling and Bcl-
2 expression during thymocyte development may explain
the extreme susceptibility of DP thymocytes to GC-induced
apoptosis, while DN and SP thymocytes are relatively resist-
ant [13].
The 2B4 T hybridoma and PD1.6 DP thymic lymphoma
cell lines are well known to be highly sensitive to GC-
induced apoptosis with more than 50% cell death within
20hrs of incubation with 100nM dexamethasone (Dex)
[3, 7, 8, 10, 14] .T h eP D 1 . 6c e l l sw e r ed e r i v e df r o mD Pt h y -
mocytes by immortalization with Radiation Leukemia Virus
(RadLV) and have been characterized to represent this stage
of thymocyte development [15]. While the mature 2B4
T hybridoma cells express basal Bcl-2 levels [3, 8], the
immature DP PD1.6 thymic lymphoma cells barely express
any Bcl-2 or Bcl-XL[8, 10, 16] .T h ea c t i v ei n t r a c e l l u l a rf o r m
(ICN) of the transcription factor Notch1 is well documented2 Advances in Hematology
to confer GC resistance upon lymphoma cells and 2B4 T
cells [3, 7]. Interestingly, we observed that overexpression of
ICN conferred GC resistance on 2B4 T cells, but not on DP
P D 1 . 6t h y m i cl y m p h o m ac e l l s[ 8]. Gene expression analysis
revealed that the Notch-regulated genes Hes1 and Deltex1
are transcribed in ICN-overexpressing 2B4 cells, but not
in ICN-overexpressing PD1.6 cells [8]. Also, overexpression
of ICN conferred GC resistance in 2B4, but not in PD1.6
cells [8]. Proteomic studies showed that 2B4 cells express
endogenous Bcl-2, with induction of the Bcl-2 member Mcl-
1 upon ICN overexpression [8] .T h el a t t e rm a yb ed u et o
activation of Akt in ICN-overexpressing 2B4 cells [7, 8], a
proteinkinasethatregulatesMcl-1expression[17].However,
PD1.6 cells, similar to DP thymocytes, do not express any of
thethreeantiapoptotic Bcl-2membersBcl-2,Bcl-XL,o rM c l-
1[ 8, 10, 16].
In the present study we show that simultaneous expres-
sion of Bcl-2 and ICN in PD1.6 cells caused induction of
Hes1 and Deltex1 transcription, with concomitant acquisi-
tion of GC resistance. These data suggest that Bcl-2 aﬀects
Notch1-mediated transcription, and both proteins need to
be present for conferring strong GC resistance.
2.MaterialandMethods
2.1. Cells. CD4+CD8+ DP PD1.6 thymic lymphoma cells
[18] and CD4−8− DN S49 thymic lymphoma cells (kindly
provided by A. Hochman, The Hebrew University of Jeru-
salem, Israel) were grown in DMEM (4.5g/l glucose) sup-
plemented with 10% heat-inactivated fetal calf serum (FCS),
2mM glutamine, 10mM HEPES, 1mM sodium pyruvate,
nonessential amino acids, and 50μM β-mercaptoethanol.
PD1.6 overexpressing ICN of Notch1 was prepared as pre-
viously described [8]. Bcl-2 overexpression was achieved by
electroporating (250V, 950μF) the cells with the pSSFV-
neo-Bcl-2 plasmid (kindly provided by Dr. Javier L´ eon,
Santander, Spain) followed by selection in 1.5mg/mL G418
(Sigma) as described [10]. Several clones were analyzed.
2.2. Reagents. Dexamethasone (Dex) was purchased from
Sigma and dissolved in ethanol at 10−2M.
2.3. Determination of Cell Death. The extent of cell death
was determined by propidium iodide (PI) uptake which was
analyzed by ﬂow cytometry in combination with altered
SSC/FSC scatter as described [8, 10]. We have previously
shown that this assay provides better representation for the
extent of lymphoma cell death than cell cycle analysis [8, 10].
PI uptake was performed with fresh cell cultures. The cells
were harvested, washed in PBS and 5μg/mL PI added prior
to analysis on ﬂow cytometry.
2.4. Reverse Transcriptase-Polymerase Chain Reaction (RT-
PCR). Total RNA was isolated from the cells using TRI
Reagent (MRC Molecular Research Center) and cDNA pre-
pared by RevertAid ﬁrst-strand cDNA synthesis kit
(Fermentas) using M-MuLV reverse transcriptase and
oligo(dT)18. PCR was performed using Taq polymerase
(Fermentas) and the following primers to: mouse GR
forward: GGAAAAGCCATTGTCAAAAGG; and reverse:
TGGCCCTCTAGAGACCACAT; mouse Deltex1 forward:
GTAAGGCTTCA-AGGGGTCGCT; and reverse: CTCAGC-
TTGATGCGTGTATAGCC; mouse Hes1 forward: GCCA-
GTGTCAACACGACACCGG; and reverse: TCACCTCGT-
TCATG-CACTCG; and mouse glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) forward: GGAGCCAAACGGG-
TCATCATCTC; and reverse: GAGGGG-CCATCCACAGT-
CTTCT.
2.5. Western Blot. Total lysate was prepared by lysing 5 ×
106 cells in 250μL Laemmli protein sample buﬀer ×
1.5. The following antibodies were applied: Bcl-2 (PC68)
(diluted 1:500) from Calbiochem; phospho-Tyr216 GSK3
(612312) (diluted 1:1000) from BD Transduction Labo-
ratories (Franklin Lakes, NJ), phospho-Ser473 Akt (cata-
log no. 9271) (diluted 1:500), phospho-Ser21/9 GSK3α/β
(catalog no. 9331) (diluted 1:1000), and phospho-Ser211
GR (catalog no. 4161) (diluted 1:1000) from Cell Signaling
Technology (Danvers, MA), GR (M20) (diluted 1:1000)
from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA),
Notch1 (mN1A) (diluted 1:1000), and α-tubulin (DM1A)
(diluted 1:20,000) from Sigma.
2.6. Statistical Analysis. Statistical analysis was performed
using Student’s t-test for paired data. A P value less than 0.05
was considered statistically signiﬁcant. Each experiment was
repeated at least 3 times.
3. Results
3.1. Bcl-2 Supports Notch-1 Transcriptional Function in
ThymicLymphomaCells. We previouslyobserved that,while
overexpressing intracellular active Notch1 (ICN) in 2B4
cells confers resistance to GC-induced apoptosis [8], ICN
overexpression in PD1.6 cells (PD1.6Notch1) had barely any
eﬀect on GC susceptibility [8]. An ensuing question was
why does not ICN confer GC resistance on PD1.6 cells? In
contrast to 2B4 cells, where ICN induces gene expression
of the Notch1 target genes Deltex1 and Hes1 [8], ICN does
not aﬀect expression of these genes in ICN-expressing PD1.6
cells (Figure 1(a) lane 2 and [8]). This indicates that Notch1
signaling is depressed in the DP PD1.6 cells, which ﬁts
with the observation that Notch1 signaling is downregulated
during the transition from DN to DP thymocytes [3, 4].
The question is why is not Notch1 active in the DP thymic
cells? Concomitant with the reduced Notch1 function, the
Bcl-2 and Bcl-XL expression levels are downregulated upon
transition from DN to DP thymocytes and reactivated again
upon transition to SP T cells [5, 6]. This prompted us to
test whether overexpression of Bcl-2 could have any eﬀect
on Notch1 function. To this end, we overexpressed Bcl-2 in
either PD1.6 or PD1.6Notch1 cells (Figure 1(b)). Indeed, we
observed that overexpression of Bcl-2 in PD1.6Notch1 cells
led to activation of the Notch target genes Deltex1 and Hes1
(Figure 1(a), lane 4), whereas, as expected, Bcl-2 overexpres-
sion alone did not activate these genes (Figure 1(a),l a n e3 ) .Advances in Hematology 3
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Figure 1: (a) Induction of Deltex1 and Hes1 expression in PD1.6 cells overexpressing both ICN-Notch1 and Bcl-2. Reverse transcriptase-
polymerase chain reaction (RT-PCR) analysis of the indicated cells. GAPDH was used as loading control. (b) Western blot analysis of Bcl-2
and Notch1 expression in PD1.6, PD1.6Bcl-2, PD1.6Notch1, and PD1.6Bcl-2Notch1 cells. α-Tubulin was used as loading control.
As a positive control for Deltex1 and Hes1 expression, we
used the immature DN S49 thymic lymphoma cells (Figure
1(a), lane 5) that endogenously express Bcl-2 and active
Notch1 [8]. PD1.6Bcl-2Notch1 cells show similar Deltex1
expression as S49 cells, but a signiﬁcantly higher level of
Hes1 (Figure 1(a), compare lane 4 with lane 5). As a negative
control,weincludedanotherPD1.6transfectantthatharbors
the dominant negative GSK3 plasmid (PD1.6GSK3βR85,
described in Spokoini et al. [8]). As expected, no activation
of the given Notch target genes is observed (Figure 1(a),l a n e
6). It should be noted that all PD1.6 transfectants contain
similar mRNA levels of the glucocorticoid receptor (GR)
as untransfected PD1.6 cells (Figure 1(a), Panel a). Taken
together, these data show that Bcl-2 can activate Notch1
transcriptional function in DP thymic cells.
3.2.PD1.6Bcl2Notch1CellsAreResistanttoGC-InducedApop-
tosis. Since ICN overexpression alone had barely an eﬀect
on the susceptibility of PD1.6 cells to GC-induced apoptosis
([8]a n dFigure 2), it was of interest to study the response
of PD1.6Bcl2Notch1 to Dex. As can be seen in Figure 2, the
expression of both Bcl-2 and Notch1 conferred resistance to
100nM Dex even after 64hrs. Bcl-2 overexpression alone led
to a delayed apoptotic response, with almost no cell death
after 20hrs, but an increasing apoptotic response after 40
and 64hrs (Figure 2). These ﬁndings support the hypothesis
thatBcl-2andNotch1cooperateinconferringGCresistance.
One of the antiapoptotic functions of Notch has been linked
to activation of the PI3K-Akt signaling pathway [19]. While
Aktisactivatedin2B4Notch1cells[7,8],itisnotactivatedin
PD1.6Bcl-2Notch1 cells (Figure 3, panel c, lanes 7-8). Thus,
the acquisition of GC resistance in these cells is not related
to Akt activation. In this context, it should be mentioned
that PD1.6 cells do not express PTEN, a phosphatase that
inhibits the PI3K-Akt signaling pathway (unpublished data).
Nevertheless Akt is not activated by Notch1, suggesting that
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Figure 2: PD1.6 cells overexpressing both ICN-Notch1 and Bcl-2
become resistant to dexamethasone (Dex)-induced apoptosis. The
cells were exposed to 100nM Dex for the indicated time periods,
followed by analysis of propidium iodide (PI) positive cells on ﬂow
cytometry. Untreated cells were used as control. ∗P<0.04 ∗∗P<
0.01.
another mechanism prevents Akt activation in these cells.
Moreover, PD1.6 cells overexpressing Bcl-2 show a slight
increase in both serine and tyrosine phosphorylation of
t h eA k tt a r g e tG S K 3α/β (Figure 3,p a n e l sd - e ,l a n e s3 - 4
and 7-8). The phosphorylation of Ser21/Ser9 is known to
inhibit the activity of GSK3 α/β. The increase in GSK3 serine
phosphorylation may contribute to GC resistance, as GSK3
is essential for GC-induced apoptosis [8]. More profoundly,
the resistance seems to be related to reduced GR expression
(Figure 3, panel b, lanes 7-8) and a reduced amount of
Ser211-phosphorylated GR (Figure 3, panel a) that is impor-
tant for its nuclear eﬀects [20]. The reduced GR expression4 Advances in Hematology
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cells. α-Tubulin was used as loading control.
mayberelatedtoelevatedexpressionofHes1,atranscription
factor known to downregulate GR expression [21]. Also,
Deltex-1 has been shown to confer GC resistance in thy-
mocytes [22] .T h eI C Nl e v e li su n a ﬀected by Dex treatment
(Figure 3,panelf).Combiningourdata,weproposethatBcl-
2 cooperates with Notch1 to confer GC resistance in PD1.6
cells by promoting Notch1-mediated transcription of Hes1
and Deltex1.
4. Discussion
In this paper we provide evidence that Bcl-2 aﬀects Notch1
function in immature thymic lymphocytes. In DP thymic
cells, Notch1 is unable to induce its target genes Deltex1 and
Hes1 in the absence of Bcl-2. When Bcl-2 is coexpressed,
Notch1 transcriptional function is activated. This is accom-
panied by the acquisition of GC resistance. This concords
withﬁndingsshowingthatbothDeltex1andHes1contribute
to GC resistance [21, 22]. Another appreciated antiapoptotic
function of Notch is linked to the activation of the PI3K-
Aktpathway[19].WhileinICN-overexpressing2B4cellsAkt
is activated [7, 8], there is no indication for Akt activation
in PD1.6Bcl-2Notch1 cells. The reason for the inability of
Notch1 to activate Akt in these cells is not known, but could
be related to high Csk activity (unpublished data). Thus,
another mechanism is likely to be responsible for Notch1-
induced GC resistance. A protrusive feature of PD1.6Bcl-
2Notch1 cells is the reduction in both GR expression and GR
Ser211 phosphorylation. The reduced GR expression may
be related to the elevated Hes1 expression in these cells.
Hes1 has been shown to downregulate GR expression in
acute T lymphoblastic leukemia [21]. Since suﬃcient GR
expression level is required for GC-induced apoptosis [13],
the reduction in GR expression and Ser211 phosphorylation
by Notch-1 overexpression is likely to contribute to GC
resistance.
Interestingly, in the original paper describing a role for
Notch1 in conferring GC resistance [3], overexpressing ICN
in AKR1010 lymphoma cells led to the induction of Bcl-2.
Thus, there may be a mutual cooperation between Notch1
and Bcl-2. A recent study by Wang et al. using pancreatic
carcinoma cells has also raised the hypothesis that Bcl-2
can aﬀect Notch1 transcriptional function [23]. These au-
thors showed that TW-37, an inhibitor of Bcl-2, attenuated
Notch1-mediated Hes1 transcription. Moreover, overexpres-
sion of Bcl-2 increased Hes1 expression, while siRNA to Bcl-
2 reduced Hes1 expression in the pancreatic cancer cells
studied [23].
Our observation that Bcl-2 is required for Notch1 func-
tion in thymic cells is important as it may explain the al-
terations in Notch1 function and GC susceptibility during
thymocyte development. In DN and SP thymocytes Bcl-2
expression and Notch1 transcriptional activity is high, while
it is low in DP thymocytes. Our data have also implications
for lymphoblastic leukemia therapy and may explain why
repressingeitherBcl-2expression(e.g.,byanBcl-2inhibitor)
or Notch function (e.g., by γ-secretase inhibitors) may
individually be suﬃcient for sensitizing the cancerous cells
to GC-induced apoptosis [11, 21, 24, 25].
Abbreviations
Dex: Dexamethasone
D N : D o u b l en e g a t i v e( C D 4 −8−)
DP: Double positive (CD4+8+)
GC: Glucocorticoids
GR: Glucocorticoid receptor
ICN: Intracellular domain of Notch1
SP: Single positive (CD4+8− or CD4−8+).
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